Virpax Pharmaceuticals (VRPX)
NASDAQ:VRPX
US Market

Virpax Pharmaceuticals (VRPX) Income Statement

90 Followers

Virpax Pharmaceuticals Income Statement

Last quarter (Q3 2023), Virpax Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Virpax Pharmaceuticals's net income was $-5.99M. See Virpax Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 4.60M$ 15.69M$ 21.85M$ 12.03M$ 4.20M$ 3.18M
Operating Income
$ -10.81M$ -15.69M$ -21.85M$ -12.03M$ -4.20M$ -3.18M
Net Non Operating Interest Income Expense
---$ -92.82K$ -147.93K$ -124.64K
Other Income Expense
$ -492.86K$ -500.28K$ -194.41K$ -62.26K$ 4.00K-
Pretax Income
$ -13.61M$ -15.19M$ -21.65M$ -12.06M$ -4.34M$ -3.31M
Tax Provision
-$ 19.42M--$ 0.00$ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -10.31M$ -15.19M$ -21.65M$ -12.06M$ -4.34M$ -3.31M
Basic EPS
$ -1.17$ -12.97$ -1.85$ -1.81$ -0.96$ -0.67
Diluted EPS
$ -1.61$ -12.97$ -1.85$ -1.81$ -0.96$ -0.67
Basic Average Shares
$ 46.86M$ 1.17M$ 11.71M$ 6.68M$ 4.51M$ 4.95M
Diluted Average Shares
$ 46.86M$ 1.17M$ 11.71M$ 6.68M$ 4.51M$ 4.95M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 4.60M$ 15.69M$ 21.85M$ 12.03M$ 4.20M$ 3.18M
Net Income From Continuing And Discontinued Operation
$ -13.61M$ -15.19M$ -21.65M$ -12.06M$ -4.34M$ -3.31M
Normalized Income
-$ -13.25M--$ -4.34M$ -3.31M
Interest Expense
----$ 147.93K$ 124.64K
EBIT
$ -13.74M$ -15.19M$ -21.65M$ -11.96M$ -4.19M$ -3.18M
EBITDA
$ -13.74M$ -15.19M$ -21.65M$ -11.96M$ -4.19M$ -3.18M
Currency in USD

Virpax Pharmaceuticals Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis